Lei L - Search Results

1

Resistance to anti-HER2 therapy associated with the TSC2 nonsynonymous variant c.4349 C > G (p.Pro1450Arg) is reversed by CDK4/6 inhibitor in HER2-positive breast cancer.

Yang Z, Feng J, Jing J, Huang Y, Ye WW, Lei L, Wang XJ, Cao WM. Yang Z, et al. Among authors: lei l. NPJ Breast Cancer. 2023 May 9;9(1):36. doi: 10.1038/s41523-023-00542-1. NPJ Breast Cancer. 2023. PMID: 37160904 Free PMC article.

2

BRCA1 Reversion Mutation Confers Resistance to Olaparib and Camrelizumab in a Patient with Breast Cancer Liver Metastasis.

Pan JN, Lei L, Ye WW, Wang XJ, Cao WM. Pan JN, et al. Among authors: lei l. J Breast Cancer. 2021 Oct;24(5):474-480. doi: 10.4048/jbc.2021.24.e39. Epub 2021 Sep 7. J Breast Cancer. 2021. PMID: 34652076 Free PMC article.

3

An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway.

Yang ZY, Yang L, Xu CW, Wang XJ, Lei L. Yang ZY, et al. Among authors: lei l. Biol Open. 2020 Jan 24;9(1):bio047662. doi: 10.1242/bio.047662. Biol Open. 2020. PMID: 31980423 Free PMC article.

4

Efficacy of fulvestrant 500 mg in Chinese postmenopausal women with advanced/recurrent breast cancer and factors associated with prolonged time-to-treatment failure: A retrospective case series.

Huang J, Huang P, Shao XY, Sun Y, Lei L, Lou CJ, Ye WW, Chen JQ, Cao WM, Huang Y, Zheng YB, Wang XJ, Chen ZH. Huang J, et al. Among authors: lei l. Medicine (Baltimore). 2020 Jul 17;99(29):e20821. doi: 10.1097/MD.0000000000020821. Medicine (Baltimore). 2020. PMID: 32702824 Free PMC article.

5

Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study.

Shao X, Zheng Y, Cao W, Shen X, Li G, Chen J, Huang Y, Huang P, Shi L, Ye W, Zou W, Lou C, Lei L, Huang J, Chen Z, Wang X. Shao X, et al. Among authors: lei l. Ann Transl Med. 2021 Apr;9(8):707. doi: 10.21037/atm-21-1340. Ann Transl Med. 2021. PMID: 33987405 Free PMC article.

6

Exploring the concepts and practices of advanced breast cancer treatment: a narrative review.

Wang X, Shao X, Huang J, Lei L, Huang Y, Zheng Y, Cao W, Chen Z. Wang X, et al. Among authors: lei l. Ann Transl Med. 2021 Apr;9(8):721. doi: 10.21037/atm-21-1458. Ann Transl Med. 2021. PMID: 33987419 Free PMC article. Review.

7

Identification of serum protein markers for breast cancer relapse with SELDI-TOF MS.

Lei L, Wang XJ, Zheng ZG, Huang J, Cao WM, Chen ZH, Shao XY, Cai JF, Ye WW, Lu HY. Lei L, et al. Anat Rec (Hoboken). 2011 Jun;294(6):941-4. doi: 10.1002/ar.21399. Epub 2011 May 4. Anat Rec (Hoboken). 2011. PMID: 21548109 Free article.

8

A significant response to a combination of trastuzumab and vinorelbine in HER2-negative metastatic breast cancer with HER2 V777L mutation.

Lei L, Ye WW, Zheng LF, Huang P, Shi L, Huang J, Zheng YB, Chen ZH, Wang XJ, Wang X. Lei L, et al. Onco Targets Ther. 2019 Apr 17;12:2931-2936. doi: 10.2147/OTT.S199931. eCollection 2019. Onco Targets Ther. 2019. PMID: 31118664 Free PMC article.

9

The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients.

Yang Z, Li N, Li X, Lei L, Wang X. Yang Z, et al. Among authors: lei l. Onco Targets Ther. 2020 Jan 28;13:853-863. doi: 10.2147/OTT.S231493. eCollection 2020. Onco Targets Ther. 2020. PMID: 32099389 Free PMC article.

10

Efficacy of Pyrotinib in HER2-Overexpressing Salivary Duct Carcinoma With Lung Metastasis: A Case Report.

Yang ZY, Huang JH, Chen B, Xu CW, Lei L, Wang XJ, Fang MY. Yang ZY, et al. Among authors: lei l. Front Oncol. 2020 Oct 2;10:559057. doi: 10.3389/fonc.2020.559057. eCollection 2020. Front Oncol. 2020. PMID: 33123470 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,105 results

Search Page

Filters